Trial Profile
Multi-national, Open-label, Active-controlled, Randomized Dose-finding Study to Evaluate Efficacy of 2 Doses of AP 12009 in Recurrent Glioma, Administered Intratumorally as Continuous High-flow Microperfusion Over 7 Days Every Other Week
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Dec 2022
Price :
$35
*
At a glance
- Drugs Trabedersen (Primary) ; Lomustine; Procarbazine; Temozolomide; Vincristine
- Indications Anaplastic astrocytoma; Glioblastoma; Glioma
- Focus Therapeutic Use
- Sponsors Isarna Therapeutics; Sirna Therapeutics
- 28 Dec 2022 According to an Oncotelic Inc media release, data from the trial were presented at the 12th AACR-JCA Joint Conference.
- 02 Dec 2019 According to Oncotelic Inc media release, data from this trial was published in the oncology journals Cancer ClinicsJournal and Annals of Hematology and Oncology Research.Also published was a peer-reviewed research article in the prestigious oncology journal Cancers.
- 18 Nov 2019 According to a Mateon Therapeutics media release, data from this study will be presented the upcoming 2019 Society for Neuro-Oncology (SNO) Annual Meeting on November 20-November 24 in Phoenix, Arizona